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Cutaneous malignant melanoma is highly invasive and capable of metastasizing to distant sites where it is
typically resistant to available therapy. While striving to prevent or eradicate melanoma, researchers have two
significant advantages not shared by those working on many other cancers. The main environmental etiological
agent, UV radiation, is known and melanocytic lesions are excisable for molecular analysis from most stages.
Yet knowledge about how UV initiates melanoma has been insufficient to achieve prevention, and the
understanding of metastatic mechanisms has been inadequate to reduce mortality. Here, we review the value
of melanoma mouse models, focusing on these critical early and late stages.
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INTRODUCTION
According to the latest Surveillance
Epidemiology and End Results report
(Espey et al., 2007), cutaneous mela-
noma is one of the three remaining
major malignancies that exhibit signifi-
cantly positive rates of increase (annual
percent change) in the United States
(Surveillance Epidemiology and End
Results Incidence Trends by Race/
Ethnicity, 1995–2004, Table I-23,
http://seer.cancer.gov/csr/1975_2004/
sections.html). It is estimated that more
than 60,000 new cases of malignant
melanoma will be diagnosed in 2008.
Worryingly, the prevalence of melano-
ma is rapidly increasing in women
under the age of 40, among whom it
has now surpassed breast cancer to
become the most prevalent malignancy
(US Prevalence Counts for 2004,
Surveillance Epidemiology and End
Results, Table I-22). This is grim news
among the highly favorable statistics
showing that many types of cancers are
on the decline, or at least leveling off. It
should sound an alarm and provide the
impetus for the melanoma research
community to seek novel and innova-
tive approaches to close the gaps in our
understanding of the biology of this
disease.
Melanoma is thought to develop in
a classical stepwise manner (Figure 1)
(Miller and Mihm, 2006), starting
with a benign nevus consisting of a
clonal population of melanocytes that
have aberrantly proliferated to a hyper-
plastic lesion that does not progress
due to cellular senescence (Mooi and
Peeper, 2006; Gray-Schopfer et al.,
2006). Once senescence is overcome,
the nevus exhibits dysplasia and can
subsequently progress to a superficial
spreading stage (radial growth phase
(RGP)) that is confined to the epidermis
and has low invasive potential. Finally,
RGP cells acquire the ability to invade
the dermis (vertical growth phase
(VGP)) and metastasize (Miller and
Mihm, 2006). Sadly, once distant me-
tastases are evident, patient prognosis
is dismal and the median survival isB6
months. It is noteworthy that clinical
data also suggest that not all melano-
mas arise in such stepwise fashion, and
metastatic disease can arise in patients
without overt primary melanoma.
The major environmental etiologic
agent for melanoma is known to be the
UV spectrum of solar radiation, which
should provide a huge advantage
over the majority of other cancers and
inform preventive strategies. The facts
that the major risk factor for melanoma
has long been appreciated and its
different disease states, from benign
nevus to metastatic primary melanoma,
are readily visible and excisable make
melanoma highly amenable to mole-
cular analysis. However, despite
these advantages, the mechanisms by
which sunlight initiates melanoma and
melanoma cells achieve the capacity to
metastasize are not adequately under-
stood. This has been due, in part, to
limitations in tissue acquisition, be-
cause human melanocytic lesions are
often archived for later analysis, and in
the availability of relevant experimen-
tal animal models of human melano-
ma. Here, we review the current and
improving status of mouse models of
human melanoma, focusing on how
appropriate models can provide key
insights concerning these critical early
and late stages of melanomagenesis.
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GENE–ENVIRONMENT INTERPLAY
IN MELANOMA INITIATION
Extensive epidemiological evidence
implicates intermittent intense expo-
sure to UVR, especially during child-
hood, as a major risk factor in the
etiology of melanoma (Maddodi and
Setaluri, 2008). Melanoma risk also has
a significant genetic component, not
only with respect to family history of
melanoma (for example, kindreds car-
rying mutations at the CDKN2A locus,
or in CDK4), but also the physical
characteristics of fair skin that easily
freckles and/or sunburns without tan-
ning and the presence of blond or
red hair, which significantly increase
the risk of melanoma. Although this
phenotypic variation in hair and skin
is likely a multigenic trait (Sulem et al.,
2007), the presence of polymorphic
variants of the MC1R (melanocortin 1
receptor) gene plays the most important
role (Lin and Fisher, 2007). Exactly
how these physical characteristics are
related to increased susceptibility to
melanoma has yet to be fully resolved.
Clearly, the presence, amount, and
type of pigment and its protective
role against genotoxic effects of UVR
are important factors in the initiation
of melanomagenesis; however, photo-
biology is much more complex. It has
been shown that melanin has both
photoprotective and photosensitizing
effects. Melanin and the process of
melanogenesis have been shown to be
photosensitizers because they generate
genotoxic reactive oxygen species
(ROS) (Maddodi and Setaluri, 2008).
This conflicting scenario clearly indi-
cates that, in addition to the pigmenta-
tion phenotype, there are other as yet
unknown background genetic elements
that contribute to the UVR-induced
transformation of melanocytes.
Ultraviolet radiation is the most ubi-
quitous environmental carcinogen. The
UVR spectrum of sunlight is divided
into three regions: UVA (320–400nm
wavelength), UVB (280–320 nm), and
UVC (200–280nm). UVC is biologi-
cally irrelevant, as it is almost comple-
tely absorbed by the atmospheric
ozone layer. Both UVA and UVB reach
the earth’s surface and have deleterious
effects on nucleic acids and proteins.
UVB is considered to be more carcino-
genic than UVA, as it directly causes
two types of DNA lesions: cyclobutane
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Figure 1. Proposed molecular alterations associated with the initiation and progression of melanoma. This illustration depicts human melanoma progression,
which is imitated in some mouse models (for example, HGF/SF-transgenic mouse), and molecular alterations that can occur at different stages. Aberrant
proliferation of normal melanocytes, presumably in response to UV radiation, results in the formation of benign or dysplastic nevi. Radial growth phase (RGP)
melanoma exhibits the ability to grow intraepidermally, followed by invasion of the dermis in the vertical growth phase (VGP), and culminating with metastasis.
Note that only about half of the melanomas are known to arise from nevi, and progression can occur without going through all the stages depicted. Several
melanoma susceptibility genes have been identified in kindreds and have been validated in mouse models. It should be noted that while heritable CDKN2A
and CDK4 mutations are often associated with melanoma, individuals with germline PTEN and TP53 mutations (Cowden and Li-Fraumeni syndromes,
respectively) develop melanoma rarely. Spontaneous DNA mutations have been observed in several genes and are postulated to be involved at different
stages of melanoma progression. Recent studies have also provided evidence for the presence of several genes whose expression is altered in melanoma by
epigenetic modulations (for example, DNA methylation and/or histone modification). We propose that epigenetic events play an important role in the
intricate gene–environment interplay associated with the initiation and progression of melanoma. Although more than 50 genes are now known to be
epigenetically modulated in melanoma, we speculate on the importance of a few cancer-related genes. We anticipate that UV-induced GEM models will
be of great value in working out details of melanoma progression (see text for details).
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pyrimidine dimers (CPDs), formed bet-
ween adjacent thymine (T) or cyto-
sine (C) residues, and 6-pyrimidine
4-pyrimidone photoproducts (6-4PP)
(Matsumura and Ananthaswamy,
2002). The CPDs are more abundant,
more carcinogenic, and less efficiently
repaired. These UVB-induced lesions
give rise to DNA mutations hallmarked
by CT-T and CC-TT transitions, the
so-called ‘‘UVB signature mutations.’’
In contrast, UVA mutates DNA indi-
rectly via absorption by non-DNA
endogenous sensitizers, which gene-
rate ROS and lead to DNA damage
(Lund and Timmins, 2007). Although
there is experimental evidence that
UVB is melanomagenic, whether UVA
also initiates and/or promotes melano-
magenesis is controversial.
The interplay of gene and environ-
ment is considered as a highly impor-
tant phenomenon underlying initiation
of melanomagenesis. UVR initiates an
acute stress response, inducing a cas-
cade of genes and pathways involved
in cellular proliferation, apoptosis,
DNA repair, and cellular survival, in
which p53 plays a major coordinating
role (Latonen and Laiho, 2005). Direct
DNA damage by UVR is believed to be
the major stimulus for the p53-depen-
dent stress response culminating in a
rapid onset of DNA repair mechanisms
(Latonen and Laiho, 2005), which
efficiently remove the CPDs and
6-4PPs within 48–72 hours post irradia-
tion (Young et al., 1996). Although
several studies have examined the
immediate genomic response of UVR-
induced stress in several skin cell types
(that is, melanocytes, keratinocytes,
and fibroblasts (Blumenberg, 2006)),
the long-term persistent response be-
yond the initial 48 hours has not been
investigated. In human skin, UV irra-
diated in vivo persistent changes in the
expression of growth factors, such as
stem cell factor and endothelin-1, and
their receptors, which are critical
players in melanocyte biology, have
been reported lasting from days to
weeks after exposure (Hachiya et al.,
2004). Little is known, however, about
the long-term UVR-induced changes in
the melanocyte transcriptome, changes
that could significantly contribute to
melanoma susceptibility.
There is a clear association between
UVR-induced DNA damage and skin
cancer. This is exemplified by a dras-
tically increased risk of skin cancer in
xeroderma pigmentosum, a syndrome
characterized by severe defects in the
nucleotide excision repair genes. In
nonmelanoma skin cancer (for example,
squamous cell carcinoma and basal cell
carcinoma), UVB signature DNA muta-
tions have been found in several genes
and are considered to play an essential
role. The most well-characterized ex-
ample is the tumor suppressor p53,
which exhibits UVB signature mutations
in a large majority of nonmelanoma skin
cancer and appears to be an initiating
event (Melnikova and Ananthaswamy,
2005). In contrast, definitive evidence
for UVB signature mutations in melano-
ma genes has been surprisingly lacking.
CDKN2A, which encodes two different
tumor suppressor proteins, p16INK4A and
p14ARF, harbors mutations in mela-
noma at dipyrimidine sites, but many
of these genetic alterations are not
UVB signature mutations. Furthermore,
C-T transition mutations in CDKN2A
are similarly observed in cancers of
internal organs protected from sun
exposure, calling into question a central
role for these mutations in UVR-induced
melanomagenesis (Hocker and Tsao,
2007). BRAF, a part of the RAS signaling
pathway and critical for the cellular
response to growth signals, has been
shown to carry mutations in a majority
of melanomas, but these are not UVB
signature mutations (Davies et al., 2002;
Hocker and Tsao, 2007). Similarly,
mutations in NRAS are found in mela-
nomas but do not carry UVB signatures
(Hocker and Tsao, 2007). Although a
small percentage of melanomas have
UVB signature mutations in TP53, such
mutations are considered as late events
during the progression of melanoma to a
higher grade (Hussein et al., 2003). This
lack of definitive evidence for UVB-
induced mutations has led to the
suggestion that UVA-induced oxidative
lesions in DNA, including BRAF and
NRAS, may be responsible for melano-
magenesis (Lund and Timmins, 2007).
However, this hypothesis is weakened
by the studies on the hepatocyte growth
factor/scatter factor (HGF/SF) transgenic
albino mouse model, which have shown
that UVB, but not UVA, is the melano-
magenic waveband (De Fabo et al.,
2004). Additional studies will be required
to resolve this important question.
It should be noted that although
in vitro studies of the effects of UVR on
melanocytes have yielded important
information, the results obtained must
be viewed with caution because
cultured melanocytes are outside
their morphological and physiological
microenvironment and lack the neces-
sary cellular interactions with other
cell types (for example, keratinocytes)
to elicit the proper responses to extra-
cellular stimuli. This problem is exem-
plified by a study that showed that
cultured and in vivo epidermal kerati-
nocytes exhibit profoundly different
responses to UVB (Enk et al., 2006).
Clearly, in-depth study of the biology
of any cell lineage is best performed
while the cells reside in their natural
morphological and physiological mi-
croenvironment. Unfortunately, purifi-
cation of melanocytes from whole mice
after exposure to UVR is a significant
challenge because the melanocytes
make up only about 1% of the cells in
the mammalian skin. Development of a
genetically engineered mouse (GEM) in
which labeled melanocytes could be
exposed to UVR in situ in the whole
animal and then isolated for detailed
molecular analyses would be of great
value in the study of the biological
effects of UVR on melanocytes.
Mouse models of UVR-induced
melanoma
Animal models of melanoma have
been instrumental in gaining the
current level of understanding of the
initiation, progression, and metastasis
of melanoma. Although several ani-
mals have been described, including
guinea pig, opossum, and Xiphophorus
fish, mouse models have provided
the most significant and most recent
advancements in melanoma research.
We will therefore focus here only on
the mouse models that have been
utilized to study the biology of UVR-
induced melanomagenesis. For a
more comprehensive review of mouse
models of melanoma, the readers are
referred to an excellent review by Larue
and Beermann (2007).
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Mouse skin is different from human
skin in some significant ways. In
human skin, melanocytes reside in the
basal layer of the epidermis, where
they make dendritic connections with
the surrounding keratinocytes. Melano-
somes are transferred from melanocyte
to keratinocytes, providing skin pig-
mentation and protection from UVR. In
mouse skin, melanocytes are located
predominantly at the base of the hair
follicles embedded in the dermis and
are only found in the epidermis of
hairless areas, such as ears, tail, and
paws. It follows that mouse melanoma
will be qualitatively different from
human melanoma. Indeed, wild-type
mice are not prone to UVR-induced
melanomagenesis, perhaps due to the
fact that their melanocytes are located
deeper in the dermis where they are
relatively well sheltered from the
penetrative reach of UVB. In some
UVR-inducible melanoma models,
such as the HGF/SF transgenic mouse,
melanocytes are aberrantly located in
the epidermis and at the dermoepider-
mal junction, resulting in more ‘‘huma-
nized’’ skin (Noonan et al., 2001).
The grafting of bona fide human
skin onto severe combined immuno-
deficient mice, although technically
arduous, offers both the relevance
of human skin and the experimental
flexibility of the mouse. Using this
approach, Berking et al. (2004) showed
that the combination of UVB and
expression of three growth factors,
basic fibroblast growth factor, stem cell
factor, and endothelin-3, rapidly
produced melanomas. It was observed
that neonatal skin produced more
aggressively invasive melanomas,
whereas adult skin grafts yielded only
in situ melanomas. These experiments
demonstrated for the first time that a
combination of physiological factors
and environmental carcinogens could
result in the transformation of human
melanocytes.
Over the last decade, the INK4A/
ARF and mitogen-activated protein
kinase (MAPK) pathways have emerged
as leading players in the etiology of
human melanoma (Bennett, 2008),
mainly due to the consistent detection
of mutations in CDKN2A, NRAS, and
BRAF (Figure 1). Gratifyingly, success
with most GEM models of human
melanoma has been achieved through
deregulation of these exact pathways.
Klein-Szanto et al. (1994) reported
the first UVR-induced melanoma
mouse model in which the melano-
cyte-specific tyrosinase promoter was
used to drive expression of the SV40
T-antigen, which inactivates both
p53 and pRb and is functionally
equivalent to the loss of the CDNK2A
locus. An activating mutation in HRAS
(HRASV12G) gives rise to melanoma
when combined with UVR, 7,12-
dimethylbenz[a]anthracene and/or sec-
ondary alterations in the p53 and/or
pRb pathways through mutations in
Ink4a/Arf (Broome Powell et al., 1999;
Chin et al., 1999; Kannan et al., 2003).
In their HRAS-transgenic mice, Kannan
et al. (2003) observed amplification
of Cdk6 in UVR-initiated melanomas
only, which was distinctly exclusive of
Ink4a loss. Further, UVR had no effect
on melanomagenesis in HRASV12G,
Ink4a/ mice, which suggested that
the pRb pathway might be the primary
target of UVR.
Hepatocyte growth factor/scatter
factor is a growth factor that regulates
melanocyte proliferation and survival
through binding to the receptor tyrosine
kinase MET, activating downstream
MAPK and PI3K pathways. Untreated
HGF/SF-transgenic mice exhibit a low
penetrance of melanoma after a long
latency. Chronic exposure of adult
HGF/SF-transgenic mice to UVR did
nothing to change this tendency. In
contrast, a single erythemal (burning)
UVR dose to neonatal HGF/SF mice
greatly exacerbated melanomagenesis
with much reduced latency (Noonan
et al., 2001). This effect was
significantly enhanced by Ink4a/Arf
deficiency (Recio et al., 2002). Impor-
tantly, the histopathology of the mela-
nomas produced in this UVR-induced
model can closely resemble human
melanoma, perhaps because of the
humanization of mouse skin by HGF/
SF (noted above), which makes this
model well suited for gene–environ-
mental interaction studies. Indeed,
in this albino mouse model, UVB, but
not UVA, was shown to be the mela-
nomagenic waveband (De Fabo et al.,
2004).
Cdk4R24C-transgenic mice give rise
to melanoma when challenged with
7,12-dimethylbenz[a]anthracene/TPA
carcinogenesis, accompanied by muta-
tions in RAS and enhanced phosphory-
lation of extracellular signal-regulated
kinase, further solidifying the notion
that activation of the MAPK pathway
and suppression of Ink4a/Arf path-
ways are two critical genetic events in
melanomagenesis (Sotillo et al., 2001).
Interestingly, the Cdk4R24C-transgenic
mice did not develop melanoma when
irradiated with UVB. This fact and the
lack of UVB signature mutations in
both NRAS and BRAF suggest that
the MAPK pathway components are
not the primary targets of UVB. More-
over, the synergy observed between
Ink4a/Arf deficiency, MAPK pathway
activation, and UVR raises the possibi-
lity that the primary targets of UVR are
outside the p53 and pRb pathways. A
concerted effort will be needed to
identify the true UVR targets to better
understand the effects of this important
environmental carcinogen on melano-
cytes and their transformation.
UVR and melanoma epigenetics
Over the years, the hunt for melanoma-
initiating genes and deregulated path-
ways has remained focused on UVR-
induced DNA damage and the resul-
tant mutations in DNA sequence.
However, these efforts have so far
failed to establish a clear association
between UVR-induced DNA damage
and melanoma initiation. It is, there-
fore, plausible to suggest that DNA
mutations alone may not fully account
for UVR-induced melanomagenesis.
Inevitably, it may be valuable to view
this problem from a new perspective
and explore other mechanisms by
which UVR mediates melanocyte
transformation. The relatively recent
discovery of the involvement of epige-
netic events in oncogenesis provides
one such alternative mechanism that
warrants consideration.
‘‘Epigenetics’’ refers to heritable
gene expression changes without al-
terations of DNA sequence. There are
two major types of epigenetic events:
modifications of the DNA itself and
changes in the chromatin packaging
proteins, the histones (Egger et al.,
2384 Journal of Investigative Dermatology (2008), Volume 128
MR Zaidi et al.
From UVs to Metastases
2004). DNA methylation occurs exclu-
sively on the carbon-5 of cytosine in a
CpG dinucleotide and is mediated by
DNA methyltransferases. CpG-dense
regions, or CpG islands, tend to locate
to the promoters of about 50% of
genes, and hypermethylation of CpG
islands is often associated with silen-
cing of gene expression. In contrast,
hypomethylation of the normally
methylated promoters gives rise to
aberrant expression of genes. Post-
translational covalent modifications of
the histones (H2A, H2B, H3, and H4),
most importantly acetylation and
methylation, at their amino-terminal
tails are also important gene-expression
regulators. Acetylation of histone tails
allows transcription factors to gain
access to DNA promoter and enhancer
regions and results in transcriptional
activation. Conversely, histone deace-
tylation leads to a tight repackaging of
the nucleosomal unit and hinders
binding of transcription factors leading
to gene silencing. Site-specific histone
H3 N-terminal tail methylation at
specific lysine residues also have been
associated with transcriptional regula-
tion (Ruthenburg et al., 2007). These
modifications are thought to bring
about transient as well as heritable
structural and expressional genetic
changes.
It has been shown that DNA methy-
lation and histone modifications coop-
erate with each other to determine
access to DNA and thus play a key
role in the control of gene expression,
DNA replication and repair, and mito-
sis (Esteller, 2007). Epigenetic modifi-
cations are well described in cancer
and are considered to be major con-
tributors to the cancer phenotype
(Esteller, 2007). Inactivation of tumor
suppressor genes and aberrant activa-
tion of oncogenes associated with the
cancer phenotype have been attributed
to promoter hypermethylation and
hypomethylation, respectively. It has
been proposed that early epigenetic
changes increase the probability that
genetic alterations will result in cancer
and thus play a major role in cancer
etiology (Feinberg, 2004).
Epigenetic modulation of gene
expression in melanoma has recently
attracted keen attention. A number of
genes are dysregulated in melanoma by
DNA methylation, as well as by modi-
fications in histones and associated
machinery (Hoon et al., 2004; Galla-
gher et al., 2005; Muthusamy et al.,
2006; Rothhammer and Bosserhoff,
2007) (Figure 1). More than fifty genes
are currently known to be silenced by
DNA methylation in melanomas (Roth-
hammer and Bosserhoff, 2007). Among
these are some of the tumor suppressor
genes long known to be associated
with melanoma, including CDKN2A,
PTEN, APC, and APAF1 (de Snoo and
Hayward, 2005; Muthusamy et al.,
2006). Aberrant expression of the nor-
mally silent MAGE (melanoma antigen
gene) in melanoma has also been
attributed to promote hypomethylation
(van Doorn et al., 2005). Moreover,
several genes involved in histone modi-
fications have been shown to be
dysregulated in melanoma, such as
those encoding the histone deacety-
lases HDAC1, HDAC2, HDAC3, and
Sirtuin 1 (Bandyopadhyay et al., 2004;
Wang et al., 2005). The precise me-
chanisms underlying these modulations
have yet to be revealed.
It is not currently known if UVR
can initiate melanomagenesis through
an epigenetic mechanism. In some
nonmelanoma cancers, silencing of
genes by hypermethylation has been
described (Belinsky, 2005), as in early
and late experimental and human lung
cancer lesions. Similarly, such a silen-
cing mechanism has been correlated
with aflatoxin adducts in hepatocellu-
lar carcinoma (Zhang et al., 2003).
Persistent epigenetic changes in res-
ponse to ionizing radiation have been
demonstrated in breast cancer (Barcel-
los-Hoff and Brooks, 2001; Tsutsumida
et al., 2004) and in experimental
chemically induced cancers (Tsutsumi-
da et al., 2004; Yamashita et al., 2004).
It can, therefore, be envisaged that
UVR influences epigenetic modulation
of gene expression in melanocytes as
well, and that at least a fraction of these
modulations persist long-term post-
irradiation and contribute significantly
to melanomagenesis.
Perhaps a link can be found bet-
ween epigenetic modulation of DNA
and UVR-induced melanomagenesis
from studies showing that a significant
percentage of UVR-initiated CPDs, and
the consequent mutations, form prefer-
entially at 5-methylcytosines within the
50-CCmG and 50-TCmG trinucleotide
sequences (Pfeifer et al., 2005). This is
effected by the preferential deamina-
tion of the 5-methylcytosine within
CPDs, which is postulated to be an
important mechanism of UVB-induced
mutagenesis (Pfeifer et al., 2005).
Moreover, it has been shown that
UVR induces global chromatin relaxa-
tion, dependent on histone acetylation
by p53-dependent recruitment of the
histone acetyltransferase p300 (Rubbi
and Milner, 2003). This chromatin
modification is an essential precursor
for nucleotide excision repair of
UVR-induced DNA damage because
it allows greater accessibility to DNA.
Aberrant persistence of such a relaxed
chromatin state at either a global or
local level could have substantial
effects on gene transcription and, ulti-
mately, on melanomagenesis. It is
anticipated that GEM models will
be designed to help experimentally
test hypotheses relating UVR-induced
epigenetic alterations to melanoma.
MOUSE MODELS OF MELANOMA
PROGRESSION AND METASTASIS
Melanoma patients face two strikingly
distinct fates: those diagnosed with
earlier stages can be completely cured
by outpatient surgery, whereas those
harboring disseminated, metastatic dis-
ease usually die within 6 months,
irrespective of treatment with currently
available chemotherapy, radiotherapy,
and/or immunotherapy. Therefore,
understanding the mechanisms that
confer a metastatic phenotype upon
melanoma cells and that allow them to
evade therapy is of paramount impor-
tance to researchers and clinicians
hoping to combat this devastating
malignancy. Lessons from the clinic
come slowly and with a heavy toll.
Relevant experimental animal models
of metastatic melanoma provide a vital
platform for molecular discovery, target
validation, and the preclinical testing
or screening of antimelanoma thera-
pies. Below, we broadly review the
available mouse models for studying
metastatic melanoma and speculate on
where the field is heading.
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Mouse models of metastatic mela-
noma have a relatively long and rich
history in cancer research. In a now
classic set of 1977 experiments, Fidler
and Kripke (1977) successfully gener-
ated individual sublines of B16 mouse
melanoma and subsequently tested
their capacity to form foci in the lungs
by intravenous injection into syngeneic
C57BL/6 mice. The differential capa-
city to colonize the lung among these
sublines demonstrated the heteroge-
neous nature of tumor cell populations.
In 1980, Hart and Fidler (1980) intra-
venously injected B16 melanoma cells
into syngeneic C56BL/6 mice whose
skin or muscle had been implanted
with tissues from various organs. B16
tumors developed preferentially in
grafts of ovarian and lung tissue in skin
as well as mouse lung organ, rather
than in renal tissue grafts or at the site
of surgical trauma, indicating that
tissue selectivity at distant sites deter-
mines the pattern of tumor metastasis
(Hart and Fidler, 1980). These studies
revived Paget’s 1889 ‘‘seed and soil’’
hypothesis and laid the foundation for
modern cancer metastasis research
(Langley and Fidler, 2007).
Since then, the repertoire of mouse
models for studying melanoma progres-
sion and developing therapies has been
greatly expanded through use of human
xenograft and GEM models (Talmadge
et al., 2007). These models can now be
categorized into four major types: (1)
human melanoma cells grafted onto
immunocompromised mice; (2) murine
melanoma, either from autochthonous
murine or GEM tumors, transplanted
into immunocompetent syngeneic
mice; (3) GEM melanoma with a
natural history more similar to human
disease; (4) murine melanoma trans-
planted into GEM hosts (Figure 2). Each
type of model has its advantages and
limitations in the study of melanoma
progression. For example, human mel-
anoma cells are overtly more relevant
to human disease than mouse melano-
ma cells, but their requirement for
transplantation into immunocompro-
mised host mice lacking normal im-
mune function and microenvironment
interactions represents a serious limita-
tion. Mouse melanoma transplanted
into syngeneic wild-type mice provides
an excellent match between tumor and
environment; however, mice are not
human. GEM model studies can be
lengthy and expensive, but are more
relevant to the natural development of
human disease and can be used to
determine the contribution of a candi-
date gene to melanoma progression
through genetic addition or subtraction.
Once a candidate gene involved in
melanoma progression/metastasis has
been selected, models employing trans-
plantation of appropriately engineered
human or murine melanoma cells are
useful to validate and dissect its func-
tion. Finally, the transplantation of
murine melanoma cells into various
lines of GEM provides the means to
experimentally manipulate the tumor
environment by genetically engineer-
ing the host (Figure 2).
Mouse models for identifying genes
involved in melanoma progression
Mouse models can greatly facili-
tate metastasis gene discovery. For
example, as an extension of the Fidler
experiments, a cancer cell line can
first be subjected to limiting dilution
cloning to generate subline populations
of single cell-derived progeny. When
transplanted into mice, these sublines
show distinct organ-specific metastatic
potential. Subsequent gene expression
profiling of these sublines, often in
concert with primary human tumor
data, can be used to mine for genes
involved in organ-specific metastasis
(Gupta et al., 2005). Alternatively, a
cancer cell line can first be subjected to
multiple transplantation cycles to select
for the ability to metastasize to a
specific organ, and then sublines can
be established (Cranmer et al., 2005).
In one elegant study, variants of mela-
noma derived from the inducible
HRAS-transgenic mouse were selected
for their metastatic propensity follow-
ing transplantation. A comparative
oncogenomics approach was then
used to identify and validate highly
relevant metastasis genes in human
melanoma, including the scaffold
protein NEDD9 (Kim et al., 2006). It
is anticipated that this approach will
ultimately provide new insight into the
nature of drug resistance in metastatic
disease.
Genetically engineered mouse mod-
els have provided surprising informa-
tion about genes contributing to
melanoma progression. As a case in
point, unexpected differences in the
consequences of expression of mem-
bers of the RAS family on melanoma
metastasis were recently revealed. One
of the earliest successful GEM models
of melanoma was driven by targeting
expression of activated HRAS to mela-
nocytes, but metastatic lesions were
very rare even in association with
inactivating mutations in Ink4a/Arf or
Tp53 (Chin et al., 2006). In contrast, a
more recent combination of melano-
cyte-specific expression of activated
NRAS and Ink4a/Arf deficiency in-
duced the development of aggressive
melanoma in which 30% of the mela-
nomas metastasized to lymph nodes
and distant organs such as the lungs
and liver (Ackermann et al., 2005).
NRAS could certainly have been pre-
dicted to have a preferential early role
in melanomagenesis based on the fact
that up to 25% of human melanomas
harbor activating mutations in NRAS,
whereas HRAS alterations have only
occasionally been detected in melano-
ma. However, these animal models
provided new insight with respect to
melanoma progression.
Those genes that have been impli-
cated in melanoma progression/
metastasis can be validated through
transplantation of genetically engi-
neered melanoma cells in which
expression of the gene in question is
either enhanced or diminished. For
example, in the study alluded to above,
knockdown of NEDD9 expression in
melanoma cells using RNAi technology
negatively impacted their ability to
proliferate, invade, and metastasize
(Kim et al., 2006). Similarly, Gupta
et al. (2005) discovered that SLUG, a
SNAIL superfamily gene, could help in
mediating the metastatic potential of
transformed, immortalized human
melanocytes and validated its role
using SLUG knockdown experiments.
However, it should be noted that when
attempting to study metastasis-specific
genes, one must be careful in distin-
guishing between those genes that
might indirectly influence melanoma
metastasis (for example, by generally
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stimulating tumor growth and/or pre-
venting apoptosis) and those that affect
only metastasis and not primary tumor
development. For example, ectopic
expression of activated NRAS would
almost certainly affect melanoma cell
proliferation. In contrast, knockdown
of MMP-1 had no effect on growth of
primary human melanoma xenografts
in nude mice, but significantly decrea-
sed the metastatic potential from the
primary site, reducing collagenase and
angiogenic activity (Blackburn et al.,
2007). Perhaps this is best illustrated by
the actions of the metastasis suppressor
genes. KISS1, originally identified in
melanoma cells, helps in maintaining
metastatic dormancy, although having
no effect on tumorigenicity or invasive-
ness (Nash and Welch, 2006).
Genetically engineered mouse mod-
els also provide novel opportunities to
assess the role of host genes on the
metastatic process. Here, mouse mela-
noma cells, engineered or not, can be
transplanted into various appropriately
modified strains of host GEM. For
example, to assess the role of nonauto-
nomous, heterotypic receptor tyrosine
kinase signaling in melanoma metasta-
sis, mice broadly expressing an HGF/SF
transgene were used as hosts for mouse
melanoma cells expressing the HGF/SF
receptor MET. These studies demon-
strated that metastatic potential under
nonautocrine signaling conditions (for
example, where MET-expressing tumor
cells are transplanted into transgenic
hosts producing HGF/SF) was equiva-
lent to autocrine conditions (for exam-
ple, where tumor cells expressing both
HGF/SF and MET are transplanted into
wild-type hosts) and demonstrated that
host cells secreting potent growth
factors can have a profound effect
on metastatic colonization (Yu and
Merlino, 2002).
Mouse models of melanoma invasion
into local tissue
As noted above, skin melanocytes are
scattered throughout the basal layer of
the human epidermis; in contrast, most
mouse melanocytes are located in hair
follicles embedded within the dermis.
The transition from RGP to VGP, a
hallmark of human melanoma progres-
sion and an important determinant of
clinical outcome, is marked by the
invasion of epidermal melanoma cells
through the basement membrane and
into the dermis (Figure 1). These factors
raise concerns about the use of mouse
models to study human melanoma
progression. Several approaches have
been employed to overcome these
limitations. GEM models have been
generated, in which melanocytes are
retained within the mouse epidermis
and at the dermoepidermal junction
through expression of either stem cell
factor (Kunisada et al., 1998) or HGF/
SF (Otsuka et al., 1998). In HGF/SF
mice, lesions resembling RGP melano-
ma and invasive melanoma are readily
observed following neonatal UV radia-
tion (Noonan et al., 2001).
Another valuable approach employs
human skin reconstructs composed of a
stratified, terminally differentiated epi-
dermal cells and dermal fibroblasts
embedded in collagen (Satyamoorthy
et al., 1999). When human melanoma
cells were incorporated into such
reconstructs and grafted onto immuno-
compromised mice, they retained the
difference between RGP and VGP
melanoma, providing an appropriate
model for addressing questions about
local invasion of melanoma. Using
this reconstruction model, Meier et al.
(2000) compared the behaviors of
normal melanocytes, RGP, VGP, and
metastatic melanoma cells: RGP mela-
noma cells grew but could not pene-
trate the basement membrane of the
epidermis; VGP primary melanoma
cells formed clusters at the dermo-
epithelial junction and invaded into
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Figure 2. Types of mouse models used for studying melanoma progression and metastasis. Models can be categorized into four basic types: (1) tumor cells
derived from human melanoma, implanted into immunocompromised mice, which are deficient in normal immune function; (2) tumor cells derived from either
autochthonous or genetically engineered mouse (GEM) melanoma, implanted onto syngeneic wild-type mice, which possess normal immune system and
stroma; (3) melanoma arising from GEM either spontaneously or via induction by a carcinogen such as UVR; (4) tumor cells derived from either autochthonous
or GEM melanomas, implanted into a GEM model, where the tumor microenvironment in the host can be manipulated by genetic engineering. Examples
of applications for these models can be found in the text.
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the dermis, but formed an irregular
basal membrane; whereas metastatic
melanoma cells rapidly proliferated
and aggressively invaded deep into
the dermis. Interestingly, basic fibro-
blast growth factor-transduced RGP
melanoma cells gained an invasive
phenotype characteristic of VGP cells
(Meier et al., 2000).
To determine which mutations are
required for melanocyte transformation
and melanoma invasion, Chudnovsky
et al. (2005) engineered human mela-
nocytes to express specific genes
implicated in human melanoma.
These cells were incorporated into the
epidermal compartment of human
skin reconstructs and then grafted
onto immunocompromised mice. They
found that a combination of mutant
NRAS, mutant CDK4, a dominant-
negative p53, and hTERT were required
to generate invasive neoplasia. To
dissect the RAS pathway in the invasive
melanoma, various downstream effec-
tors were used to replace activated
NRAS in the gene transfer combination
mentioned above. Replacement of
RAS with activated PI3K still generated
invasive melanocytic hyperplasia,
whereas mutant BRAF did not. These
data demonstrate that the grafting of
human melanoma/skin reconstructs
onto mice provides a relevant huma-
nized model to study local invasion
of melanoma and the genes that
regulate it.
Mouse models of immune response in
metastasis and tumor dormancy
Syngeneic transplantation models have
been employed in the study of the
immune response during melanoma
metastasis. A common approach is to
immunize mice by implanting an auto-
chthonous tumor, remove the tumor
after an appropriate growth period, and
then challenge the mice by injecting
melanoma cells into another sub-
cutaneous site. The incidence of sub-
cutaneous and metastatic tumors is
then used to assess protection. Notably,
Donawho et al. (2001) used this
approach to show that such immuniza-
tion was able to protect mice from
subcutaneous tumor challenge, but
insufficient to prevent spontaneous
metastasis melanoma. The underlying
mechanisms can be elaborated in this
model by genetically engineering or
depleting immune cells.
Immunocompromised mice provide
a unique advantage in the study of
human immune response to melano-
ma. Mice that have very low residual
immune activity, such as severe com-
bined immunodeficient mice, allow
transplantation of both human melano-
ma cells and immune cells. This
provides a platform to test the interac-
tion between specific human immune
cells and melanoma cells in the meta-
static process. As an example, Sabze-
vari and Reisfeld (1993) reported that
injection of human cytotoxic T cells
suppressed lung metastasis of human
melanoma subcutaneously implanted
into severe combined immunodeficient
mice.
The frequent recurrence of tumors
many years after treatment is a well-
recognized but poorly understood
characteristic of cancer. This most
important clinical phenomenon is en-
abled by the capacity of residual tumor
cells to remain dormant for prolonged
periods before recurrence. Recent evi-
dence suggests that the immune system
helps to sustain tumor dormancy and
thus delay cancer progression. As
described above, immune cells of mice
immunized with subcutaneously im-
planted tumors can target and kill most
tumor cells in the challenge injection.
However, one study has shown that
some residual cells still persist and that
the immune system keeps them dor-
mant (Rabinovsky et al., 2007). Virus-
activated dendritic cells were found to
effectively prolong the dormancy of
highly metastatic B16F10 melanoma
and enhance survival in a mouse model
by strongly enhancing CD8þ T-cell
response (Shibata et al., 2006). How
immunosurveillance prevents melano-
ma cells from expansion during dor-
mancy and how these cells ultimately
escape dormancy and recur remain
critical, yet unanswered, questions.
Preclinical mouse models of melanoma
treatment
Preclinical models can be used to
assess the efficacy of arising anticancer
therapies, to test that molecularly tar-
geted drugs actually hit their targets,
and as a discovery tool in the develop-
ment of new clinical agents, biomar-
kers, and assays. It would therefore be
advantageous that such a model mi-
mics the entire spectrum of human
melanoma progression and be able to
predict the response of human mela-
noma to a wide variety of therapeutic
agents and approaches. In reality, it is
clear that no single animal model is
suited for all things. Therefore, many of
the types of mouse models discussed
above, which focus on a particular
stage of progression or on a specific
mechanism of melanoma metastasis,
may turn out to be useful for preclinical
studies.
For the development of antimelano-
ma immunotherapy, the subcutaneous
or intravenous transplantation of B16
mouse melanoma cells into syngeneic
mice remains a standard in the field.
The B16 models have been used to test
many different types of vaccines and
immune cell transfer protocols. For
example, mice have been immunized
with a recombinant adenovirus encod-
ing human dopachrome tautomerase
(DCT, formally known as TRP-2) and
then challenged with either intrave-
nous injection or subcutaneous implan-
tation of B16 cells. The vaccine
protected all of the mice from pulmon-
ary tumor formation in the former
group, and half of the mice from
subcutaneous tumor formation in the
latter group (Kochenderfer and Gress,
2007).
Inoculation of murine melanoma
cells into syngeneic mice and xeno-
grafts of human melanoma cells into
immunocompromised mice are both
employed for the assessment of the
efficacy of antimelanoma small mole-
cules and monoclonal antibody drugs.
It should be noted that because of the
differences in how drugs are processed
or metabolized in mice (pharmacoki-
netics), the maximum tolerated dose of
a given drug might be much higher in
mice than in any patient. Therefore, a
positive response to a relatively high
dose of a drug in a preclinical mouse
setting may not be achievable in
melanoma patients. In an attempt to
avoid bringing unusable drugs into
clinical trials, more ‘‘humanized’’
pharmacokinetic protocols are being
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considered to more closely reflect the
actual maximum tolerated dose of
drugs used in human patients (Jansen
et al., 1999; Ramirez-Montagut et al.,
2006; Donawho et al., 2007).
The recent identification of tumor-
initiating cells, so-called cancer stem
cells, has brought exciting new insights
into cancer biology, and along with it
new candidate targets into preclinical
modeling. This specific population of
cells is thought to be capable of
indefinite self-renewal and differentia-
tion, driving tumor formation. More-
over, like normal stem cells, tumor-
initiating cells could possess the ability
to resist drug treatment and survive in a
state of relative quiescence over a
dormant period (Lobo et al., 2007). In
an attempt to identify tumor-initiating
cells in melanoma, Schatton et al.
(2008) has proposed that melanoma-
initiating cells are enriched in a cellular
population expressing the transporter
molecule ABCB5. As proof of their
stem-like behavior, Schatton et al.
(2008) showed that ABCB5þ human
melanoma cells could preferentially
form tumors after serial transplantation
and limiting dilution experiments in
immunocompromised mice. They
further demonstrated that these putative
melanoma stem cells were sensitive to
treatment with a monoclonal antibody
directed against ABCB5 after transplan-
tation into immunocompromised mice.
This study fuels hope that tumor-initiat-
ing cells and/or their markers can serve
as effective therapeutic targets. It is
anticipated that preclinical mouse mod-
els will be used to further validate these
new targets and to test those therapies
designed to attack them.
The incorporation of bioimaging
technology such as optical imaging
(fluorescence and bioluminescence),
radiological imaging (micro-CT,
micro-PET, high-resolution MRI), and
ultrasound into preclinical models
will greatly accelerate the screening
process by monitoring disease progres-
sion in vivo and providing inform-
ation on tissue anatomy, histological
changes associated with treatment,
drug distribution, tumor metabolism,
and molecular targeting (Brindle,
2008). Moreover, mouse models are
being designed to fully exploit bioima-
ging, allowing metastatic cells and their
interactions with the microenvironment
to be precisely tracked. This point is
well illustrated by Kaplan et al. (2005)
in their study of the premetastatic
niche. By transplanting green fluores-
cent protein-labeled bone marrow-de-
rived hematopoietic progenitor cells
and red fluorescent protein-labeled
tumor cells into lethally irradiated
mice, they showed that hematopoietic
progenitor cells home to tumor-specific
sites and form cell clusters, creating a
permissive niche before tumor cell
arrival. This study reveals that hemato-
poietic progenitor cells are intimately
involved in the metastatic process, a
finding that carries significant potential
clinical implications.
CONCLUSION
In this review, we have tried to argue
for the need to focus melanoma re-
search on mechanisms by which UVR
initiates melanoma, to improve preven-
tion strategies, and by which metastatic
melanoma evolves and evades thera-
peutic eradication, to improve inter-
vention strategies. In addition, we have
attempted to illustrate how these efforts
are being significantly facilitated
through the creation and use of a
variety of mouse models. However,
the obstacles, like the stakes, continue
to be formidable.
While melanoma incidence con-
tinues to increase at an alarmingly
accelerating rate, there exists a major
gap in our current knowledge with
regard to how solar or artificial UVR
initiates melanoma, considerably ham-
pering our ability to accurately deter-
mine the risk of melanoma from
various UVR sources. Increased use of
tanning salons has been linked to
increased risk for melanoma in multi-
ple studies, but direct cause and effect
remains elusive and controversial, con-
fusing public health policy and legisla-
tion regarding tanning sunbed use.
Sunscreen use is consistently recom-
mended for protection from sunlight,
but there is considerable controversy
over its effectiveness against melanoma
(Lund and Timmins, 2007). And be-
cause of the ambiguities associated
with remembering and/or recording
sun exposure history, the absence of
molecular biomarkers of such exposure
severely hinders attempts to accurately
assess melanoma risk and thus prevent
its development.
Despite the problems with under-
standing the initiation of early-stage
melanoma, it is readily curable. In
contrast, the prognosis of patients with
metastatic melanoma could not be
worse. Advanced melanoma is notorious
for its resistance to all forms of available
therapy, highlighting the need for radi-
cally new approaches and drugs, the
development of which has been
obstructed by the lack of relevant
experimental and preclinical animal
models. Currently, preclinical analysis
of candidate antimelanoma therapies
relies almost exclusively on models in
which human melanoma cells pre-
viously adapted to cell culture are
subcutaneously transplanted into inade-
quate immunocompromised host mice,
with the readout for treatment success
being tumor growth at the primary site.
This overly simplistic representation of
advanced melanoma has not been
particularly useful for identifying new
drugs or predicting their efficacy.
We believe that creative and judi-
cial incorporation of genetically engi-
neered melanoma cells and animal
models will be instrumental to both
understanding and preventing melano-
ma initiation and progression. Mouse
models now provide outstanding op-
portunities for filling long-standing
gaps in knowledge and resolving con-
troversies regarding the different UVR
wavelengths (De Fabo, 2006), child-
hood sun exposure, pigmentation,
sunscreen protection, and tanning sal-
on risk. Built on a foundation of
continual improvements fueled by fresh
molecular and mechanistic insights,
mouse models are also now among
the best tools for identifying novel and
successful strategies for prevention,
early detection, and treatment of mel-
anoma. There is, therefore, reason to be
optimistic about the clinical prospects
for melanoma patients as new basic
revelations from human and mouse
models are translated into efficacious
antimelanoma therapy.
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